

Regional bulletin for the availability of antimalarial medicines: First Quarter 2016

Number 1
2016



Regional Platform on
Access and Innovation
for Health Technologies
PRAIS

www.paho.org/prais

This bulletin is developed through a collaborative effort between the National Malaria Control Programs of the Region of the Americas, PAHO/WHO and SIAPS/USAID to facilitate sharing of information between countries in the Americas. The objectives of the bulletin are to increase awareness of stocks of antimalarial medicine, generate stock out alerts and promote exchanges and donations of antimalarial medicines between countries.

This bulletin is based on information provided by countries in South and Central America who participate in the Amazon Malaria Initiative (AMI) and are members of the Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA). The bulletin offers information on the availability of medicines in central and regional medical stores that allow countries' decision makers to assure uninterrupted supply.

The following tables detail the availability of antimalarial medicines for each country. Stock out is considered zero availability in the storerooms.

The indicator of months of availability is calculated by each country by dividing the availability of medicines by the average monthly consumption or distribution. The average consumption is found by dividing the distribution or consumption over the previous year by 12.

This first bulletin includes information from seven countries, three from South America and four from Central America. Seven countries sent central and regional level data.



Pan American
Health
Organization



World Health
Organization

REGIONAL OFFICE FOR THE
Americas



USAID
FROM THE AMERICAN PEOPLE



SIAPS
Systems for Improved Access
to Pharmaceuticals and Services

Availability of medicines for the first quarter, 2016

Medications			BRAZIL					COLOMBIA					GUATEMALA					
			Central			Department		Central			Departamental		Central			Department		
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Medicamento Obligatorio de acuerdo a normas nacionales (1=si ; 0=no)	Existencia (en unidades) de medicamentos	Disponibilidad en meses de acuerdo al consumo	Existencia en unidades de medicamentos	Disponibilidad en meses de acuerdo al consumo	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	13,830	12.29	10,837	10.39	1	0	0.00	277	0.74						
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	16,380	12.67	10,365	8.59	1	0	0.00	643	0.57						
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	19,650	15.02	11,305	9.26	1	0	0.00	921	0.74						
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	38,400	14.04	20,552	10.86	1	0	0.00	2,190	0.23						
	005	Artesunate 50 mg tablet																
	006	Artesunate 100 mg tablet																
	007	Artesunate 250 mg tablet																
	008	Artesunate+ SP (Children)																
	009	Artesunate+ SP (Adolescent)																
	010	Artesunate+ SP (Adults)																
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.	1	380	5.94	782	11.50											
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.	1	400	6.25	806	11.85											
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.	1	0	0.00	305	4.49											
	014	Artesunate-Mefloquine 100/220 mg x 6 tablet.	1	0	0.00	553	3.69											
	015	Mefloquine 250 mg tablet																
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet																
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	1331,500	5.66	1168,358	5.72	1	858,300	12.89	90,178	1.51	1	10,444	0.00	17,737	1.72	
	018	Chloroquine phosphate 100 mg tablet																
	019	Primaquine phosphate 5 mg tablet	1	354,500	4.86	406,814	7.32	1	46,285	2.5	36,336	4.08	1	6	0.0	8,123	0.99	
	020	Primaquine phosphate 7.5 mg tablet																
	021	Primaquine phosphate 15 mg tablet	1	546,500	2.05	1343,848	6.70	1	120,000	2.18	204,746	2.18	1	846	0.00	5,164	0.48	
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules																
	023	Artesunate rectal 50 mg						1	0	0.00	1,468	3.50						
	024	Artesunate rectal 100 mg									20							
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	1	7,658	2.39	23,902	8.20	1	1,200	6.28	1,383	2.23						
	026	Clindamycin Hydrochloride 300 mg Capsule	1	0	0.00	15,926	18.12											
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable	1	47,400	7.88	49,189	9.49											
	028	Clindamycin Hydrochloride 150 mg Capsule																
	029	Clindamycin 75mg/5mL suspension																
	030	Doxycycline 100 mg Capsule																
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable							1	200	2.00	1,024	0.98					
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable																
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable																
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable	1	13,500	6.35	35,435	20.78												
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable																	
036	Quinine Sulfate 300mg tablet							1	10,000	25.19	37,852	11.34						
037	Quinine Sulfate 500 mg tablet	1	98,000	44.38	69,770	37.07												

Source: Consolidated Report from Countries

Availability of medicines for the first quarter, 2016

Medications			HONDURAS					NICARAGUA				
			Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet										
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet										
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet										
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	0	144	0.00							
	005	Artesunate 50 mg tablet										
	006	Artesunate 100 mg tablet										
	007	Artesunate 250 mg tablet										
	008	Artesunate+ SP (Children)										
	009	Artesunate+ SP (Adolescent)										
	010	Artesunate+ SP (Adults)										
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.										
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.										
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.										
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.										
	015	Mefloquine 250 mg tablet										
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet	1	0	0.00	0	0.00					
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	444,400	6.91	81,028	2.37	1	2,379,499	25.11	743,986	3.25
	018	Chloroquine phosphate 100 mg tablet										
	019	Primaquine phosphate 5 mg tablet	1	381,050	15.99	33,540	1.91	1	1,396,447	20.34	327,303	2.56
	020	Primaquine phosphate 7.5 mg tablet										
	021	Primaquine phosphate 15 mg tablet	1	642,170	12.63	87,284	3.01	1	455,185	5.87	344,912	2.99
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules										
	023	Artesunate rectal 50 mg										
	024	Artesunate rectal 100 mg										
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	0	5	0.00	0	0.00					
	026	Clindamycin Hydrochloride 300 mg Capsule						1	81,390	0.62	183,911	1.28
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	93,354	2.88	40,096	1.20
	028	Clindamycin Hydrochloride 150 mg Capsule										
	029	Clindamycin 75mg/5mL suspension										
	030	Doxycycline 100 mg Capsule						1	2,467,766	6.54	739,003	1.96
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	1	257	14.28	0	0.00	1	298	2.92	217	1.37
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable										
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable											
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable											
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable											
036	Quinine Sulfate 300mg tablet	1	0	0.00	0	0.00						
037	Quinine Sulfate 500 mg tablet											

Source: Consolidated Report from Countries

Availability of medicines for the first quarter, 2016

Medications			PANAMA					PERU				
			Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	0	0.00	0	0.00					
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	0	0.00	0	0.00					
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	0	0.00	0	0.00					
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	120	7.50	792	49.50					
	005	Artesunate 50 mg tablet						1	2,623	0.28	31,456	3.39
	006	Artesunate 100 mg tablet										
	007	Artesunate 250 mg tablet						1	1,128	0.28	14,167	3.48
	008	Artesunate+ SP (Children)										
	009	Artesunate+ SP (Adolescent)										
	010	Artesunate+ SP (Adults)										
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.										
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.										
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.										
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.										
	015	Mefloquine 250 mg tablet						1	19,690	2.23	32,192	3.65
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet										
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	50,000	52.08	0	0.00	1	3,330	0.05	148,782	2.05
	018	Chloroquine phosphate 100 mg tablet										
	019	Primaquine phosphate 5 mg tablet	1	0	0.00	0	0.00					
	020	Primaquine phosphate 7.5 mg tablet						1	172,120	49.46	92,351	26.54
	021	Primaquine phosphate 15 mg tablet	1	50,000	37.20	0	0.00	1	287,320	3.48	93,491	1.13
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	1,470	122.50	2,705	225.42
	023	Artesunate rectal 50 mg										
	024	Artesunate rectal 100 mg										
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						1	800	8.89	36	0.40
	026	Clindamycin Hydrochloride 300 mg Capsule										
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable										
	028	Clindamycin Hydrochloride 150 mg Capsule										
	029	Clindamycin 75mg/5mL suspension										
	030	Doxycycline 100 mg Capsule										
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable										
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable										
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable											
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable						1	0	0.00	10	0.05	
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable											
036	Quinine Sulfate 300mg tablet						1	18,540	24.46	16,396	21.63	
037	Quinine Sulfate 500 mg tablet											

Source: Consolidated Report from Countries

Indicators reported for the first quarter, 2016

INDICATORS	Brasil		Colombia		Guatemala		Honduras		Nicaragua		Panamá		Perú	
	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart
No. of department warehouses that report medication availability data.		27		33		29		14		19		15		32
% of regional stores that report stockout in one or more antimalarials required by the Standard Treatment Guidelines (STG).		30%		100%		62%		29%		26%		100%		44%
Number of medicines required in the Standard Treatment Guidelines (STG)	16	16	11	11	3	3	6	6	7	7	7	7	10	10
Number of STG medicines that are available.	13	16	6	11	3	3	4	3	7	7	3	1	9	10
% of STG medications available	81%	100%	55%	100%	100%	100%	67%	50%	100%	100%	43%	14%	90%	100%
% of STG medications not available	19%	0%	45%	0%	0%	0%	33%	50%	0%	0%	57%	86%	10%	0%
% of STG medications with availability less than or equal to the minimum security stock (3 months)	31%	0%	73%	73%	100%	100%	33%	83%	43%	86%	57%	86%	50%	40%
% of STG medications which are overstocked (more than 24 months of availability)	6%	6%	9%	0%	0%	0%	0%	0%	14%	0%	29%	14%	30%	20%

This bulletin was elaborated within the framework of AMI/RAVREDA with assistance from PAHO/WHO, specifically the Medicines and Health Technologies (HSS/MT) unit and the Regional Malaria Program (CHA/VT) and the USAID funded program Systems for Improved Access to Pharmaceuticals and Services (SIAPS). Data for the report was sent by the National Malaria Control Programs of the participating countries. The consolidation and editing of the bulletin was completed by the regional team of the PAHO/WHO Strategic Fund, which utilized the previous format developed by DIGEMID and SIAPS/USAID as a reference

